Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-01-08
2008-10-14
Spector, Lorraine (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387900, C424S130100, C424S133100, C424S135100, C424S158100
Reexamination Certificate
active
07435799
ABSTRACT:
The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-α and that are capable of neutralizing TNF-α at low concentrations. Preferably, the TNF-α binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).
REFERENCES:
patent: 4603106 (1986-07-01), Cerami et al.
patent: 4677063 (1987-06-01), Mark et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4822776 (1989-04-01), Cerami et al.
patent: 4870163 (1989-09-01), Rubin et al.
patent: 4879226 (1989-11-01), Wallace et al.
patent: 5075236 (1991-12-01), Yone et al.
patent: 5118500 (1992-06-01), Hanel et al.
patent: 5145676 (1992-09-01), Fahey, III et al.
patent: 5183657 (1993-02-01), Buurman
patent: 5223395 (1993-06-01), Gero
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5288852 (1994-02-01), Yamada et al.
patent: 5360716 (1994-11-01), Ohmoto et al.
patent: 5436154 (1995-07-01), Barbanti et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5616321 (1997-04-01), Hector et al.
patent: 5616688 (1997-04-01), Cerami et al.
patent: 5644034 (1997-07-01), Rathjen et al.
patent: 5650147 (1997-07-01), Wolpe et al.
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5672347 (1997-09-01), Aggarwal et al.
patent: 5686428 (1997-11-01), Eriksson et al.
patent: 5698195 (1997-12-01), Le et al.
patent: 5698419 (1997-12-01), Wolpe et al.
patent: 5700466 (1997-12-01), Wolpe et al.
patent: 5703206 (1997-12-01), Wolpe et al.
patent: 5730975 (1998-03-01), Hotamisligil et al.
patent: 5741484 (1998-04-01), Cerami et al.
patent: 5741488 (1998-04-01), Feldman et al.
patent: 5750105 (1998-05-01), Newman et al.
patent: 5760186 (1998-06-01), Cerami et al.
patent: 5795967 (1998-08-01), Aggarwal et al.
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 5817763 (1998-10-01), Cerami et al.
patent: 5849873 (1998-12-01), Cerami et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5863535 (1999-01-01), Cerami et al.
patent: 5919452 (1999-07-01), Le et al.
patent: 5932412 (1999-08-01), Dillner et al.
patent: 5942222 (1999-08-01), Wolpe et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5959087 (1999-09-01), Rathjen et al.
patent: 5989836 (1999-11-01), Cerami et al.
patent: 5994510 (1999-11-01), Adair et al.
patent: 6015557 (2000-01-01), Tobinick et al.
patent: 6015558 (2000-01-01), Hotamisligil et al.
patent: 6019969 (2000-02-01), Cerami et al.
patent: 6046309 (2000-04-01), Cerami et al.
patent: 6090382 (2000-07-01), Salfeld et al.
patent: 6114517 (2000-09-01), Monia et al.
patent: 6177077 (2001-01-01), Tobinick et al.
patent: 6235281 (2001-05-01), Stenzel et al.
patent: 6258562 (2001-07-01), Salfeld et al.
patent: 6270766 (2001-08-01), Feldman et al.
patent: 6277969 (2001-08-01), Le et al.
patent: 6284471 (2001-09-01), Le et al.
patent: 6309640 (2001-10-01), Cerami et al.
patent: 6379666 (2002-04-01), Tobinick
patent: 6416757 (2002-07-01), Rathjen et al.
patent: 6419927 (2002-07-01), Cerami et al.
patent: 6419934 (2002-07-01), Tobinick
patent: 6419944 (2002-07-01), Tobinick
patent: 6423321 (2002-07-01), Tobinick
patent: 6428787 (2002-08-01), Tobinick
patent: 6448380 (2002-09-01), Rathjen et al.
patent: 6451983 (2002-09-01), Rathjen et al.
patent: 6498237 (2002-12-01), Rathjen et al.
patent: 6509015 (2003-01-01), Salfeld et al.
patent: 6537549 (2003-03-01), Tobinick
patent: 6555111 (2003-04-01), Wallach et al.
patent: 6593458 (2003-07-01), Rathjen et al.
patent: 6790444 (2004-09-01), Le et al.
patent: 6803039 (2004-10-01), Tsuji et al.
patent: 6835823 (2004-12-01), Le et al.
patent: 7008623 (2006-03-01), Bonnefoy et al.
patent: 7192586 (2007-03-01), Bander
patent: 2003/0204066 (2003-10-01), Junming et al.
patent: WO 95/03827 (1995-02-01), None
patent: WO 97/30088 (1997-08-01), None
patent: WO 98/22137 (1998-05-01), None
patent: WO 98/51344 (1998-11-01), None
patent: WO 01/94585 (2001-12-01), None
patent: WO 02/12502 (2002-02-01), None
patent: WO 03/042247 (2003-05-01), None
patent: WO 03/083061 (2003-10-01), None
Boyle, et al., “I. A Novel Monoclonal Human 1gM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Facter-α”, Cellular Immunology, 1993, pp. 556-568, vol. 152.
Boyle, P, et al., “II. The B5 Monoclonal Autoantibody Binds to Cell Surface TNFα on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope”, Cellular Immunology, 1993, pp. 569-581, vol. 152.
Breedveld, FC, et al., “Monoclonal antibody therapy of inflammatory rheumatic diseases”, British Medical Bulletin, 1995, pp. 493-502, vol. 51, No. 2.
Brennan, FM, et al., “TNFα-A Pivotal Role in Rheumatoid Arthritis?”, British Journal of Rheumatology, 1992, pp. 293-398, vol. 31.
Brensing-Kuppers, J, et al., “The human immunoglobulin κ locus on yeast artificial chromosomes (YACs)”, Gene, 1997, pp. 173-181, vol. 191.
Bringhman, TS, et al., “Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Application for Affinity Purification, Immunoassays, and as Structural Probes”, Hybridoma, 1987, pp. 489-507, vol. 6, No. 5.
Cox, JPL, et al., “A directory of human germ-line Vχsegments reveals a strong bias in their usage”, Eur. J. Immonol., 1994, pp. 827-836, vol. 24.
Dick, AD, et al., “Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina”, Eur. J. Immonol., 1996, pp. 1018-1025, vol. 26.
Elliott, MJ, et al., “Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis facter α (cA2) versus placebo in rheumatoid arthritis”, The Lancet, 1994, pp. 1105-1110, vol. 344.
Elliott, MJ, et al., “Repeated therapy with monoclonal antibody to tumour necrosis facter α (cA2) in patients with rheumatoid arthritis”, Lancet, 1994, pp. 1125-1127, vol. 344.
Elliott, MJ, et al., “Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Facter α”, Arthritis and Rheumatism, 1993, pp. 1681-1690, vol. 36, No. 12.
Exley, AR, et al., “Monoclonal antibody to TNF in severe septic shock”, Lancet, 1990, pp. 1275-1277, vol. 335.
Feldman, M, et al., “Anti-Tumor Necrosis Facter-α Therapy of Rheumatoid Arthritis”, Advances in Immunology, 1997, pp. 283-350, vol. 64.
Fendly, BM, et al., “Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor”, Hybridoma, 1987, pp. 359-369, vol. 6, No. 4.
Fomsgaard, A., et al., “Auto-Antibodies to Tumour Necrosis Factor α in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections”, Scand. J. Immunol., 1989, pp. 219-223, vol. 30.
Griffiths, AD, et al., “Human anti-self antibodies with high specificity from phage display libraries”, The EMBO Journal, 1993, pp. 725-734, vol. 12, No. 2.
Hammerle, AF, et al., “Serum Proteins and Cytokines for Prediction of Sepsis?”, Second Vienna Shock Forum, 1989, pp. 715-718.
Herve, P, et al., “Phase I-II Trial of a Monoclonal Anti-Tumor Necrosis Facter α Antibody for the Treatment of Refractory Severe Acute Graft-Versus-Host Disease”, Blood, 1992, pp. 3362-3368, vol. 79, No. 12.
Hinshaw, LB, et al., “Survival of Primates in LD100Septic Shock Following Therapy With Antibody to Tumor Necrosis Factor (TNFα)”, Circulatory Shock, 1990, pp. 279-292, vol. 30.
Johnson, G, et al., “Kabat Database and its applications: 30 years after the first variability plot”, Nucle
Huse William D.
Marquis David
Vasserot Alain P.
Watkins Jeffry D.
Applied Molecular Evolution
Martinez Alejandro
Shafer Shulamith H
Spector Lorraine
Wiskerchen MaryAnn
LandOfFree
TNF-α binding molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TNF-α binding molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TNF-α binding molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4010583